Publication Name	World Journal of Gastroenterology
Manuscript ID	82802
Country	South Korea

Received	2022-12-28 03:01
Peer-Review Started	2022-12-28 03:02
To Make the First Decision
Return for Revision	2023-03-08 03:54
Revised	2023-03-20 11:05
Second Decision	2023-04-17 05:19
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-04-17 08:07
Articles in Press	2023-04-17 08:07
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-04-27 03:40
Publish the Manuscript Online	2023-05-11 08:05

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pediatrics
Manuscript Type	Minireviews
Article Title	Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
Manuscript Source	Invited Manuscript
All Author List	Eun Sil Kim and Ben Kang
Funding Agency and Grant Number
Corresponding Author	Ben Kang, MD, PhD, Associate Professor, Department of Pediatrics, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu 41944, South Korea. benkang@knu.ac.kr
Key Words	Anti-tumor necrosis factor; Infliximab; Adalimumab; Crohn’s disease; Pediatric
Core Tip	In pediatric Crohn’s disease (CD), the choice of biologic agents should be made more carefully to achieve the therapeutic goal. This review article focuses on comparing the efficacy of induction and maintenance of remission, safety profile, immunogenicity, preference, and compliance between infliximab and adalimumab in pediatric CD.
Publish Date	2023-05-11 08:05
Citation	Kim ES, Kang B. Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease. World J Gastroenterol 2023; 29(18): 2784-2797
URL	https://www.wjgnet.com/1007-9327/full/v29/i18/2784.htm
DOI	https://dx.doi.org/10.3748/wjg.v29.i18.2784

Full Article (PDF)	WJG-29-2784.pdf
Full Article (Word)	WJG-29-2784.docx
Manuscript File	82802_Auto_Edited-JLW.docx
Answering Reviewers	82802-Answering reviewers.pdf
Audio Core Tip	82802-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	82802-Conflict-of-interest statement.pdf
Copyright License Agreement	82802-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	82802-Language certificate.pdf
Supplementary Material	82802-Copyright permission.pdf
Peer-review Report	82802-Peer-review(s).pdf
Scientific Editor Work List	82802-Scientific editor work list.pdf